日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance)

帕唑帕尼治疗恶性胸膜间皮瘤患者的 II 期研究:NCCTG N0623(联盟)

Parikh, Kaushal; Mandrekar, Sumithra J; Allen-Ziegler, Katie; Esplin, Brandt; Tan, Angelina D; Marchello, Benjamin; Adjei, Alex A; Molina, Julian R

A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia.

肌醇治疗支气管发育不良吸烟者的随机 IIb 期试验

Lam Stephen, Mandrekar Sumithra J, Gesthalter Yaron, Allen Ziegler Katie L, Seisler Drew K, Midthun David E, Mao Jenny T, Aubry Marie Christine, McWilliams Annette, Sin Don D, Shaipanich Tawimas, Liu Gang, Johnson Evan, Bild Andrea, Lenburg Marc E, Ionescu Diana N, Mayo John, Yi Joanne Eunhee, Tazelaar Henry, Harmsen William S, Smith Judith, Spira Avrum E, Beane Jennifer, Limburg Paul J, Szabo Eva

Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study

简报:一项针对晚期非小细胞肺癌患者的MTOR抑制剂替西罗莫司单药治疗的II期“机会窗口”一线研究(NCCTG研究)

Reungwetwattana, Thanyanan; Molina, Julian R; Mandrekar, Sumithra J; Allen-Ziegler, Katie; Rowland, Kendrith M; Reuter, Nicholas F; Luyun, Ronnie F; Dy, Grace K; Marks, Randolph S; Schild, Steven E; Jett, James R; Adjei, Alex A

Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer

疾病进展日期确定对晚期肺癌无进展生存期估计的影响

Qi, Yingwei; Allen Ziegler, Katie L; Hillman, Shauna L; Redman, Mary W; Schild, Steven E; Gandara, David R; Adjei, Alex A; Mandrekar, Sumithra J

Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma

拉帕替尼和拓扑替康 (LapTop) 治疗铂类难治性/耐药性卵巢癌和原发性腹膜癌患者的 II 期临床试验

S John Weroha, Ann L Oberg, Katie L Allen Ziegler, Shaker R Dakhilm, Kendrith M Rowland, Lynn C Hartmann, Dennis F Moore Jr, Gary L Keeney, Prema P Peethambaram, Paul Haluska

Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668

Akt 抑制剂 SR13668 的 0 期临床化学预防试验

Joel M Reid, Chad A Walden, Rui Qin, Katie L Allen Ziegler, John L Haslam, Roger A Rajewski, Roger Warndahl, Cindy L Fitting, Daniel Boring, Eva Szabo, James Crowell, Marjorie Perloff, Ling Jong, Brent A Bauer, Sumithra J Mandrekar, Matthew M Ames, Paul J Limburg; Cancer Prevention Network

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426

培美曲塞联合贝伐单抗用于晚期非小细胞肺癌患者二线治疗的 II 期临床试验:NCCTG 和 SWOG 研究 N0426

Alex A Adjei, Sumithra J Mandrekar, Grace K Dy, Julian R Molina, Araba A Adjei, David R Gandara, Katie L Allen Ziegler, Philip J Stella, Kendrith M Rowland Jr, Steven E Schild, Ralph G Zinner

Endpoints in phase II trials for advanced non-small cell lung cancer

晚期非小细胞肺癌 II 期试验的终点

Mandrekar, Sumithra J; Qi, Yingwei; Hillman, Shauna L; Allen Ziegler, Katie L; Reuter, Nicholas F; Rowland, Kendrith M Jr; Kuross, Steven A; Marks, Randolph S; Schild, Steven E; Adjei, Alex A

Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study

评估谷胱甘肽代谢基因对接受铂类化疗初始治疗后晚期非小细胞肺癌患者预后的影响:一项基于NCCTG-97-24-51的研究

Yang, Ping; Mandrekar, Sumithra J; Hillman, Shauna H; Allen Ziegler, Katie L; Sun, Zhifu; Wampfler, Jason A; Cunningham, Julie M; Sloan, Jeff A; Adjei, Alex A; Perez, Edith; Jett, James R